Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Protalix BioTherapeutics (PLX) over the last 13 years, with Q3 2025 value amounting to $22000.0.

  • Protalix BioTherapeutics' Other Operating Expenses fell 9846.58% to $22000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 million, marking a year-over-year decrease of 25071.46%. This contributed to the annual value of $77000.0 for FY2019, which is 9650.64% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Other Operating Expenses stood at $22000.0, which was down 9846.58% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Other Operating Expenses registered a high of $1.4 million during Q3 2024, and its lowest value of -$3.9 million during Q2 2025.